Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
FDA+ channel feed
Alvotech fails pre-approval inspection for its proposed Humira interchangeable biosimilar
3 years ago
Pharma
FDA again finds Amylyx's ALS data lacking ahead of unusual second adcomm, while stressing dire need for treatments
3 years ago
Pharma
FDA expands approval for Vertex's CF drug Orkambi to infants under two years of age
3 years ago
Pharma
Biosimilar giant Biocon gets hit with 483 for issues at sites in Malaysia and India
3 years ago
Manufacturing
Two years after a refuse-to-file, Y-mAbs lands an FDA adcomm for its 2nd neuroblastoma treatment
3 years ago
Amneal asks FDA to approve another new formulation of Parkinson’s combo drug
3 years ago
Pharma
Azurity Pharmaceuticals continues its win streak as it bags another approval from the FDA
3 years ago
Pharma
Top Boehringer Ingelheim drug gets FDA approval in rare skin disease
3 years ago
Pharma
Federal judge rules against FDA in major stem cell oversight case
3 years ago
Law
Once valued at more than $5B, Intarcia Therapeutics sees all of its execs depart and its final shot at FDA denied
3 years ago
Pharma
Sanofi's Paul Hudson scores an FDA OK for a rare disease drug — after a lengthy R&D odyssey
3 years ago
Pharma
After disappointing Wall Street last year, Denali touts new biomarker data hoping to forge clear path to FDA
3 years ago
R&D
Pharma-backed patient groups sue HHS over copay assistance programs
3 years ago
Law
Florida sues FDA over dragging its feet on Canadian drug import program's approval
3 years ago
Pharma
Corrected: FDA allows Curis to restart enrolling patients in leukemia trial as shares tumble 9%
3 years ago
Pharma
Sanofi nabs priority review for hemophilia A program as pharma awaits FDA decision
3 years ago
R&D
Beam reveals what tripped up its base-edited, off-the-shelf CAR-T as it tries to clear FDA hold
3 years ago
Cell/Gene Tx
Drug manufacturers must submit reports on quality problems to FDA. Almost half of sites still don't, new report finds
3 years ago
Manufacturing
Incyte secures second FDA approval for bile duct cancer drug in mutated cancer type
3 years ago
Pharma
Coin flip: Top analyst gives Amylyx ALS drug a 50% chance at approval as rare second adcomm approaches
3 years ago
R&D
French penny stock will no longer knock on FDA door for approval in a certain type of blood cancer
3 years ago
R&D
BioMarin nets conditional approval for valrox in Europe, marking the first hemophilia gene therapy
3 years ago
Cell/Gene Tx
House investigates Trump’s ‘inappropriate’ pressure on FDA during the pandemic
3 years ago
Coronavirus
Interchangeability without switching studies: FDA explains why a new Lucentis biosimilar may be a game-changer
3 years ago
Pharma
First page
Previous page
74
75
76
77
78
79
80
Next page
Last page